Dexcom Inc (NASDAQ: DXCM) started the day on Thursday, with a price increase of 0.10% at $138.01, before settling in for the price of $137.87 at the close. Taking a more long-term approach, DXCM posted a 52-week range of $74.75-$142.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 28.80%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 15.91%. This publicly-traded company’s shares outstanding now amounts to $385.40 million, simultaneously with a float of $377.42 million. The organization now has a market capitalization sitting at $53.20 billion. At the time of writing, stock’s 50-day Moving Average stood at $130.56, while the 200-day Moving Average is $115.14.
Dexcom Inc (DXCM) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Medical Devices Industry. Dexcom Inc’s current insider ownership accounts for 2.10%, in contrast to 99.40% institutional ownership. According to the most recent insider trade that took place on Apr 15 ’24, this organization’s EVP Strategy and Corporate Dev sold 1,990 shares at the rate of 137.81, making the entire transaction reach 274,242 in total value, affecting insider ownership by 42,377. Preceding that transaction, on Apr 08 ’24, Company’s President CEO and Chairman sold 49,633 for 138.30, making the whole transaction’s value amount to 6,864,136. This particular insider is now the holder of 283,893 in total.
Dexcom Inc (DXCM) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 12/31/2023, the organization reported 0.17 earnings per share (EPS) for the three months, surpassing the consensus estimate (set at 0.15) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.39 per share during the current fiscal year.
Dexcom Inc’s EPS increase for this current 12-month fiscal period is 15.91% and is forecasted to reach 2.24 in the upcoming year.
Dexcom Inc (NASDAQ: DXCM) Trading Performance Indicators
Let’s observe the current performance indicators for Dexcom Inc (DXCM). It’s Quick Ratio in the last reported quarter now stands at 2.48. The Stock has managed to achieve an average true range (ATR) of 4.23. Alongside those numbers, its PE Ratio stands at $105.29, and its Beta score is 1.20. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 14.69. Similarly, its price to free cash flow for trailing twelve months is now 103.93.
In the same vein, DXCM’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 1.31, a figure that is expected to reach 0.40 in the next quarter, and analysts are predicting that it will be 2.24 at the market close of one year from today.
Technical Analysis of Dexcom Inc (DXCM)
If we take a close look at the recent performances of Dexcom Inc (NASDAQ: DXCM), its last 5-days Average volume was 2.89 million that shows plunge from its year to date volume of 2.98 million. During the previous 9 days, stock’s Stochastic %D was recorded 72.80% While, its Average True Range was 4.30.
Raw Stochastic average of Dexcom Inc (DXCM) in the period of the previous 100 days is set at 86.24%, which indicates a major rise in contrast to 68.95% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 24.74% that was lower than 33.62% volatility it exhibited in the past 100-days period.
